Pharmaceutical and Biotech

Our approach to pharmaceutical and biotech communications

Pharmaceutical and biotech communications exist in an environment where trust is conditional, scrutiny is constant and visibility alone is meaningless without credibility.

Scientific claims are interrogated publicly. Regulatory milestones are analysed in real time. Media narratives shape how clinicians, policymakers, investors and patients interpret progress long before commercial impact is felt. At the same time, misinformation and over-simplification can spread faster than evidence.

For pharmaceutical companies and biotech firms, the central communications challenge is being clearly understood, responsibly represented and independently validated at moments that genuinely matter.

PR Agency One is a specialist pharmaceutical and biotech PR agency, focused on earned media-led communications for complex, regulated and reputationally sensitive environments. We help life sciences organisations communicate products, pipelines and scientific progress with clarity, authority and commercial discipline.

We are an award-winning PR consultancy based in Manchester and London, working with pharmaceutical, biotech and life sciences leadership teams in the UK and internationally.

PR Agency One’s work is built on creative effectiveness – the belief that communications should be both intellectually rigorous and commercially accountable.

We are a team of earned-media-led pharmaceutical and biotech communications specialists, comfortable operating in environments where accuracy, balance and scrutiny are expected.

Our approach is senior-led, strategy-first and grounded in evidence. We focus on creating communications that can withstand regulatory, media and stakeholder interrogation while still cutting through complexity.

Earned-first strategy and reputation-led communications

In pharmaceutical and biotech communications, trust is transferred, not claimed. Earned media remains the most credible and defensible route to visibility, particularly for regulated products and complex science.

Our work prioritises media relations, thought leadership and reputation management that places independent scrutiny at the centre of the communications process. We focus on shaping narratives that journalists, clinicians and opinion-formers can interrogate with confidence, rather than relying on promotional amplification.

As AI-driven search and discovery tools increasingly present authoritative journalism and structured editorial sources, earned media also plays a defining role in how pharmaceutical and biotech organisations are discovered, summarised and understood.

Translating complex science into clear, credible narratives

Communicating science effectively is about accuracy, relevance and context.

We specialise in translating complex scientific concepts, clinical data and regulatory developments into narratives that are intelligible without being reductive. Our work respects the intelligence of specialist audiences while remaining accessible to non-scientific stakeholders where appropriate.

This includes the communication of mechanism of action, trial design, data significance and pipeline strategy, ensuring that what is said publicly aligns with what is known, emerging or still under investigation.

Product, pipeline and milestone communications

Pharmaceutical and biotech organisations face very different communications demands across the product lifecycle. We support clients from early stage science through to commercial maturity, with strategies designed for each phase.

For early stage and growth phase biotech firms, communications are often about establishing scientific credibility and long-term intent before commercial visibility. We help articulate research platforms, therapeutic focus and innovation narratives in ways that support investor confidence, partnership discussions and scientific reputation.

At key inflection points, including clinical readouts, regulatory submissions and approvals, communications require particular care. These moments attract heightened scrutiny, and the way information is framed can influence interpretation well beyond the immediate announcement.

For approved products and launches, earned media supports understanding, adoption and category leadership. Our work focuses on responsible visibility, avoiding exaggerated claims while still clearly articulating value and relevance.

Operating confidently in regulated environments

We are comfortable operating in environments where communications are closely scrutinised and accountability is expected.

Our teams work within established regulatory and ethical frameworks, ensuring communications are evidence-led, appropriately balanced and clearly contextualised. We understand the realities of regulated communications and the importance of aligning closely with in-house legal, medical and compliance teams.

Rather than treating regulation as a constraint, we see it as a discipline that improves clarity, credibility and trust.

Stakeholders and audiences we engage

Effective pharmaceutical and biotech communications recognise that reputation is shaped across multiple audiences simultaneously. Our work is designed to maintain coherence and credibility across groups that often consume information differently.

We engage with clinicians and healthcare professionals, researchers and scientific institutions, regulators and policymakers, specialist and national media, and corporate and investor audiences where relevant. Strategies are built to ensure that messages remain consistent, accurate and defensible, regardless of channel or stakeholder.

Why earned media matters more than ever

In high-scrutiny sectors, earned media delivers more than coverage. It provides independent validation, reputational resilience and long-term authority.

As automated discovery tools increasingly draw on journalistic and trade sources, earned media now shapes not only public perception but also how organisations are represented in AI-generated summaries and other decision support tools. Credible, third party coverage therefore plays a direct role in misinformation resilience and narrative generation.

Measurement, accountability and commercial outcomes

Through OneEval, our proprietary evaluation framework, we assess PR impact across awareness, understanding, reputation and downstream commercial indicators. This enables senior teams to understand not just what activity has taken place, but what difference it has made.

Measurement is built into strategy from the outset, providing clarity, accountability and evidence of value.

International pharmaceutical and biotech communications

Through One Network, PR Agency One delivers pharmaceutical and biotech communications across more than 26 countries.

Our international model combines central strategic leadership with local, in-market expertise, ensuring that communications are culturally relevant, media-appropriate and consistently governed. This approach supports multi-market launches, corporate reputation programmes and global milestone communications without sacrificing local credibility.

Why PR Agency One

PR Agency One is differentiated by focus, discipline and delivery:

• A specialist pharmaceutical and biotech PR agency
• Award-winning consultancy based in Manchester and London
• Earned-media-led, credibility-first approach
• Proven experience in regulated, high-risk environments
• Senior-led consultancy model with clear accountability
• Proprietary measurement through OneEval and international delivery through One Network

We are deliberately distinct from advertising-led or performance-driven healthcare agencies. Our work is rooted in reputation, trust and measurable outcomes.

A conversation at the right level

If you are assessing how earned media can support pharmaceutical or biotech communications – from early pipeline storytelling to regulatory milestones and long-term reputation – we welcome an exploratory conversation.

Our work typically begins with senior-level discussions focused on risk, opportunity and impact, rather than predefined tactics.
PR Agency One – pharmaceutical and biotech communications built for scrutiny, credibility and results.